Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499449 | 0.90 | POLB (0.34) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL912774 | 0.79 | BRAF (0.35) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL28695087 | 0.73 | BRAF (0.31) | BRAF | |
| SCHEMBL27838905 | 0.72 | ESR1 (0.36) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL27872518 | 0.72 | — | — | |
| SCHEMBL12497786 | 0.71 | POLB (0.35) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1461847 | 0.71 | BRAF (0.54) | BRAF | |
| SCHEMBL1490997 | 0.71 | PSEN1 (0.35) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL914368 | 0.70 | BMP1 (0.35) | BRAFPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL913476 | 0.69 | BRAF (0.34) | BRAFPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394795-B2 | Pyrazole [3, 4-B] pyridine Raf inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2265610-B1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003859-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2011-01-06 | — | — | US | disclosed |
| EP-2265574-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265610-A1 | PYRAZOLE [3, 4-B]PYRIDINE RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111279-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111280-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885PSEN1 2468/4885PSEN2 2763/4885 |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885PSEN1 4729/4885PSEN2 4737/4885 |
| US-20110092479-A1 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885PSEN1 2322/4885PSEN2 2773/4885 |
| US-20110003859-A1 | N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER | BRAF, RAF1, ARAF | BRAF 1/4885PSEN1 4825/4885PSEN2 4767/4885 |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885PSEN1 2213/4885PSEN2 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.